GlobeNewswire by notified

Bang & Olufsen releases preliminary Q3 numbers and adjusts revenue outlook for the financial year. Positive earnings expected for the full year despite lower revenue

Share

Bang & Olufsen’s preliminary Q3 2023/24 result for group revenue is DKK 614m, a 2% year-on-year decline in local currencies and flat year-on-year growth in product revenue.

The revenue outlook for the financial year 2023/24 (ending 31 May 2024) is adjusted due the company’s sales being impacted by slower-than-expected improvement of macroeconomic conditions in the company’s key markets in Europe. Further, Bang & Olufsen does not foresee a significant recovery of the Chinese economy to materialise in 2023/24 as previously anticipated. Consequently, revenue growth (in local currencies) for the financial year 2023/24 is now expected to be between -8% and -5% (previously in the lower end of 0% to 9%).

The company also narrows the ranges for the EBIT margin before special items and free cash flow. EBIT margin before special items is now expected to be between 0% and 2% (previously 0% to 6%), while free cash flow is expected to be between DKK -50m and DKK 10m (previously in the lower end of DKK -50m to DKK 100m). Preliminary Q3 2023/24 results for the EBIT margin before special items is 1.8% as the company continues to deliver an improved gross margin.

CEO Kristian Teär comments:


“We are improving our profitability and robustness as we progress with our strategic transition towards higher margin revenue. However, we do not see the expected improvement in macroeconomic conditions in some of our key markets in Europe and in our single biggest market, China. This is impacting our sales and are the primary reasons we are adjusting our outlook for the financial year.” 

“Once again, we deliver a quarter with a record-high gross margin. This is a result of our strategic efforts to improve the experience in our branded channels with our retail partners and strengthen our luxury positioning and product portfolio. This is our fourth consecutive quarter with margins above 50%. The improvement makes us more resilient as a business and enables us to continue with our strategic transition.”

The preliminary results for Q3 2023/24 (9M 2023/24) are as follows:

  • Revenue of DKK 614m, equivalent to -2% y-o-y growth in local currency (9M: DKK 1,933m, equivalent to -7% y-o-y growth in local currency)
  • Product revenue of DKK 543m, corresponding to a 0% y-o-y growth in local currency (9M: DKK 1,711m, corresponding to a -5% y-o-y growth in local currency)
  • Gross profit of DKK 326m, corresponding to an improvement of DKK 49m y-o-y (9M: DKK 1,023m, corresponding to an improvement of DKK 140m y-o-y)
  • Gross margin of 53.2%, corresponding to an improvement of 9.6 pp. (9M: 52.9%, corresponding to an improvement of 11.0 pp.)
  • EBIT before special items of DKK 11m, corresponding to an improvement of DKK 54m y-o-y (9M: DKK 48m, corresponding to an improvement of DKK 162m y-o-y)
  • EBIT margin before special items of 1.8%, corresponding to an improvement of 8.6 pp. (9M: 2.5%, corresponding to an improvement of 7.9 pp.)
  • Free cash flow of DKK 5m (9M: DKK -32m)
  • Like-for-like sell-out decline of 2% y-o-y (9M: Like-for-like sell-out growth of 3% y-o-y)

The company adjusts its outlook as follows:

  • Revenue growth in local currencies:
-8% to -5%
(Previously in the lower end of 0% to 9%)
  • EBIT margin before special items:
0% to 2%
(Previously 0% to 6%)
  • Free cash flow:
DKK -50m to DKK 10m
(Previously in the lower end of DKK -50m to DKK 100m)

The outlook is subject to uncertainty related to consumer sentiment. In addition, geopolitical uncertainty has increased. The pace of the economic recovery in China is also subject to uncertainty.

The outlook is further subject to the following assumptions:

  • No worsening of market situation in China for the remainder of the fiscal year (previously improved market conditions in China in H2 23/24).
  • No worsening of macroeconomic conditions in Europe and US for the remainder of the fiscal year (previously macroeconomic conditions in Europe and the US will improve during the fiscal year).
  • Timely launch of two product innovations in fiscal Q4.
  • No impact on product availability due to geopolitical changes.
  • Exchange rates against DKK, including in particular USD, CNY and EUR, in line with current exchange rate levels, overall.
  • No upward pressure on component and logistics costs.

The company will release its quarterly financial report for 9M 2023/24 on 10 April 2024 as planned.

For further information, please contact:

Cristina Rønde Hefting        
Director, Investor Relations        
Phone: +45 4153 7303        

Jens Gamborg
Head of Global Sustainability & Communications
Phone: +45 2496 9371

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

Results of the Ordinary and Extraordinary Shareholders’ Meeting23.4.2024 18:00:00 CEST | Press release

Press release – regulated information Ghent, BELGIUM, April 23, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext - BTLS) (the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, held its ordinary and an extraordinary shareholders' meeting today at 10:00 CEST at the Company’s seat. The legally required presence quorum was reached for the extraordinary shareholders’ meeting. The shareholders approved all items on the agenda of the meetings. All documents relating to the shareholders’ meetings can be consulted on the website of the Company. The minutes will be made available in due course. For further information, please contact: Toon Musschoot, Head of Investor Relations and Communications T: +32 (0)9 274 54 00 E: IR@biotalys.com About Biotalys Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and food and aiming to provide alt

HiddenA line styled icon from Orion Icon Library.Eye